ArticlePhysiological research2025
Protective mechanisms of exosomes derived from human umbilical cord mesenchymal stem cells in bronchopulmonary dysplasia.
Article in Physiological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The molecular mechanisms of gas signaling molecules in bronchopulmonary dysplasia related lung injury.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchopulmonary dysplasia (BPD) is characterized by reduced alveolar formation and disordered matrix remodeling. Currently, there are no effective therapeutic approaches for it. This study aims to explore the protective effect of exosomes derived from human umbilical cord mesenchymal stem cells on BPD by regulating the immune response and inflammatory pathways of macrophages. PKH26-labeled human umbilical cord mesenchymal stem cell line exosomes (hUCMSC-Exos) were co-cultured with RAW264.7 cells, which were assigned to the following groups: normoxia, normoxia + NLRP3 activator (Nigericin), normoxia + hUCMSC-Exos + Nigericin, hyperoxia, hyperoxia + hUCMSC-Exos, and hyperoxia + hUCMSC-Exos + Nigericin. Cell viability and cytokine expression in cell supernatant were measured for each group. PKH26 exosome staining confirmed successful uptake of hUCMSC-Exos by RAW264.7 cells. hUCMSC-Exos demonstrated protective effects against reductions in cell viability induced by both Nigericin and hyperoxia. Cells in the Hyperoxia group showed significantly increased expression of inflammatory cytokines IL-33, IL-6, IL-1beta, TNF-alpha, and IL-18 compared to those in the Normoxia group, along with elevated mRNA and protein levels of NLRP3, ASC, caspase-1, IL-18, IL-1beta, and ATF4. The Hyperoxia + hUCMSC-Exos group exhibited reduced expression of IL-33, IL-6, IL-1beta, TNF-alpha, IL-18 and IL-33, IL-6, IL-1beta, TNF-alpha, and IL-18 compared to the Hyperoxia group. In contrast, the Hyperoxia + hUCMSC-Exos + Nigericin group showed elevated levels of IL-33, IL-6, IL-1beta, TNF-alpha, and IL-18, as well as increased expression of NLRP3, ASC, caspase-1, IL-18, IL-1beta, and ATF4 compared to the Hyperoxia + hUCMSC-Exos group. hUCMSC-Exos mitigate hyperoxia-induced damage to lung macrophages by reducing endoplasmic reticulum stress, inhibiting NLRP3 inflammasome expression, and regulating inflammatory cytokine release, that may be potentially useful in BPD. Key words Bronchopulmonary dysplasia " Exosomes " Human umbilical cord mesenchymal stem cells " Macrophages " NLRP3.
Indexed as
Identifiers
40698659PMC12462705What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.